FHTXFoghorn Therapeutics Inc.

$322M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+206.7% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$101M-7637.1% margin

Net Income

-$101M-7681.6% margin

EPS (Diluted)

$-2.78

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$54M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$520M

Total Liabilities

$423M

Stockholders' Equity

$97M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$430,000	+206.7%
Gross Profit	$1M	-$57M	+102.3%
Operating Income	-$101M	-$69M	-47.0%
Net Income	-$101M	-$69M	-47.3%

FHTX FY 2021 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena